Leucokinin VIII,1mg

Catalog No.: C08-0411-708
Manufacturer No.: RP10698
Manufacturer Name: GenScript USA Inc
Quantity: 1
Unit of Measure: EA

Price: $59.05

List Price: $65.61

The effects of leucokinin-VIII were qualitatively and quantitatively similar in six tubule segments containing no stellate cells V(t) decreased from 37.8+/-7.

Enjoy exclusive benefits including discounted pricing on orders by contacting our Sales Executives to open an account.

Current Stock:

Quantity:

Adding to cart… The item has been added

Description
Specifications

The effects of leucokinin-VIII were qualitatively and quantitatively similar in six tubule segments containing no stellate cells; V(t) decreased from 37.8+/-7.0 mV to 3.4+/-0.6 mV, R(t) decreased from 8.8+/-2.1 kOmegacm to 1.7+/-0.2 kOmegacm, and DP(Cl) increased from 5.8+/-2.6 mV to 50.0+/-2.1 mV. Thus, stellate cells are not required for signaling or mediating the effects of leucokinin in Malpighian tubules of Aedes aegypti. The results further support previous observations that principal cells signal the effects of leucokinin-VIII to increase the Cl(-) conductance of the paracellular pathway through septate (or tight) junctions.

UPC:: 51131703
Condition:: New
Availability:: 3 Days
Weight:: 1.00 Ounces
HazmatClass:: No
WeightUOM:: LB
MPN:: RP10698

Cenmed Satisfaction Guarantee

At Cenmed, your confidence and satisfaction are paramount. We guarantee the quality and reliability of our extensive range of clinical and laboratory supplies. If you're not completely satisfied with your purchase, we offer a straightforward return process and dedicated support to resolve your concerns promptly. Our commitment ensures that you can order with confidence, knowing that Cenmed is dedicated to superior service and customer satisfaction. Trust us to meet your needs with every order, backed by our promise of excellence. Learn more in Help & FAQs.

"Cenmed provides me access to the same products/services normally reserved for much larger labs than mine. I was presently surprised by their product offering."